FINWIRES · TerminalLIVE
FINWIRES

TYO:4523

5 stories mentioning TYO:4523

Every FINWIRES story that references TYO:4523, newest first.

Asia

UK, Japan Enter Into GBP 18 Billion Deal to Boost Clean Energy, Jobs, Next-Generation Tech

British and Japanese leaders are set to finalize an 18 billion pound sterling agreement expected to create "tens of thousands of new jobs" in offshore wind, infrastructure, and finance, according to a statement on Saturday.Under the deal, several Japanese companies committed 5-year investments to UK projects, including 2 billion pounds sterling by Mitsubishi Estate(TYO:3481), 3.8 billion pounds sterling by Mitsui Fudosan (TYO:8801), and 500 million pounds sterling by Nomura Real Estate (TYO:3231).Additional pledges include Mizuho Financial's 3 billion pound sterling expansion of its UK operations, Eisai's (TYO:4523) 48 million pound sterling government-backed facility upgrade, and an offshore wind compact facilitating up to 9 billion pound sterling for floating wind projects in the North and Celtic Seas.Legal & General also broke ground on a 135 million pound sterling London housing project in partnership with Nomura (TYO:8604), marking the firm's first UK homebuilding venture.Prime Minister Keir Starmer will host his Japanese counterpart and business delegates in London before the G7 meeting in France, where over 10 commercial and government agreements are expected to be signed.

Nikkei 225TYO:3231TYO:3481TYO:4523TYO:8604TYO:8801
Asia

Jefferies Adjusts Eisai's Price Target to 4,000 Yen From 5,000 Yen, Keeps at Hold

Eisai (TYO:4523) has an average rating of hold and mean price target of 4,877.86 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

TYO:4523
Asia

Eisai Posts 88 Billion Yen Leqembi Revenue For Fiscal 2025

Eisai (TYO:4523) said global revenue for Alzheimer's treatment Leqembi reached 88 billion yen on a preliminary basis for the year ended March, according to a Thursday filing on the Tokyo Stock Exchange.The U.S. accounted for 44.6 billion yen of sales, followed by Japan at 24.4 billion yen and China at 12.4 billion yen.

TYO:4523
Asia

Eisai, Merck's Phase 3 Kidney Cancer Drug Combo Trial Fails to Meet Survival Endpoints

Japanese pharmaceutical firm Eisai (TYO:4523) and U.S.-based Merck's experimental combination therapies failed to meet the dual primary endpoints of progression-free survival and overall survival in a Phase 3 trial.The trial was evaluating first-line treatment for advanced clear cell renal cell carcinoma, a form of kidney cancer that accounts for approximately 80% of all cases, according to a joint statement on Tuesday.The LITESPARK-012 study tested two regimens: Keytruda plus Lenvima plus Welireg, and MK-1308A (a co-formulation of Keytruda with an investigational antibody) plus Lenvima, against the established combination of Keytruda and Lenvima in 1,688 patients.An interim analysis revealed that neither experimental combination met the study's two primary goals of improving overall survival and progression-free survival compared with the standard treatment.

TYO:4523
Asia

Jefferies Adjusts Eisai's Price Target to 5,000 Yen from 4,600 Yen, Keeps at Hold

Eisai (TYO:4523) has an average rating of hold and mean price target of 5,052.86 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

TYO:4523